Scientists have analyzed the crystal structure of MFN1 fragment

It is reported that Professor Gao Song research group from the Zhongshan University Cancer Center center analyzed the crystal structure of MFN1 fragment in different triphosphate guanosine (GTP) hydrolysis condition and clarified the mechanism of MFN1 hydrolysis GTP and proposed MFN1 mitochondrial outer membrane embolization mediated model. Recently, the relevant research has been published online in the journal Nature, which also publishes other studies on recombinant human proteins.

The body consists of tens to hundreds of trillion cells, of which the vast majority of cells contain an important "organ" called "mitochondria" (organelle), which is the "energy plant" of cells. Mitochondrial fusion relies on a protein "machine" implementation called mitofusin. This machine is anchored on the surface of the mitochondria to achieve docking and fusion of different mitochondria by using a small molecule compound "fuel" called GTP. Mitofusin machines sometimes suffer from a "part" failure due to genetic mutations, leading to mitochondrial fusion disorders and the associated human disease.

Researchers use "X-ray crystal diffraction" and other technologies to make mitofusin form as sugar and salt-like crystals (volume only one thousandth of a million) for diffraction experiments. They finally observed microstructure of mitofusin machine and found it can adjust their own structure through the consumption of GTP fuel and can adsorb each other.

The study reveals an important process of basic life activities that has important guiding roles for people to explore the causes of related diseases and to develop appropriate clinical approaches. By the way, Flarebio offers good-quality recombinant proteins like recombinant App at good prices.

Understanding more about the dinoflagellate's mystical genome

Dinoflagellates usually have a good life when in good times. They live free-floating in the ocean or symbiotically with corals, or as lunch to a host of mollusks, tiny fish and coral species. Some of them make glowing waves at night since they are bioluminescent. However, things will get worse when conditions are wrong. Dinoflagellates poison shellfish beds with red tides and abandon coral reefs to a slow, bleached death.

This happens more and more frequent. In order to find out the answer, UConn marine ecologist Senjie Lin led his research team and sequence the complete genome of dinoflagellate species S. kawagutii, becoming the first one who had done so. The results can be found in journal Science which also publishes other studies on recombinant human proteins.

The species of S. kawagutii is an important endosymbiont of coral reefs, providing them with sugars and nutritious compounds. When it is not present, the corals bleach white, cannot grow and tend to die. However, although metabolic wastes from the coral host provide an enriched supply of nutrients in the otherwise nutrient-poor oceanic habitat, the relation seems to be not enssential S. kawagutii. The researchers guess that when the dinoflagellates don't like the conditions, they can jump ship and turn themselves into impervious little cysts and wait for the right time to ecolonize corals. This performance also can explain that S. kawagutii has an awfully large genome for a symbiont. Usually endosymbionts and parasites depend on the cellular machinery of their hosts and lack many genes that free-living organisms have. So here comes the question: Why does S. kawagutii have so many? No one can explain now.

After analyzing the entire genome of S. kawagutii and comparing it with the genetic codes of related organisms which can be better understood, the team found some surprising things. For instance, they found genes associated with sexual reproduction. S. kawagutii typically reproduces asexually as other dinoflagellates do. A single dinoflagellate will simply split in two. However, when the dinoflagellates turn into cysts, they would reproduce sexually first, which mixes their genetic material with others, maybe in the hope that some of the offspring will gain traits better suited to the stressful environment. But sex related genes have never been found in other dinoflagellates. The results of the study show that K. kawagutii actually has had the bad times in corals.

They also found that S. kawagutii has a gene regulatory system that looks like it could regulate certain genes in corals. That's to say, the dinoflagellates may be manipulating their host's genetic expression in order to make the conditions more comfier for them.

Understanding the S. kawagutii's genome can help researchers better study other dinoflagellates which act many different roles in the ocean ecosystem, thus explaining how the environment changes affecting their way of life. Flarebio offers high-quality recombinant proteins such as recombinant APP at competitive prices.

Motor proteins pause at the ends of microtubules and stimulate their growth

Researchers at Penn State suggest that motor proteins which pause at the ends of microtubules and produce pushing forces can also stimulate their growth. According research using recombinant mouse proteins, the function of the proteins is a critical component in understanding cell division and nerve branching and growth.

Kinesins are found in multicellular organisms. They are a family of motor proteins. They act as little engines within the cells and transport molecular cargo along microtubules. The microtubules are hollow cylinders of the protein tubulin. They are dynamic and can grow and shrink when the cell change shape.

The researchers are trying to understand more about the motor and what makes the sequences unique since they carry out so many vital functions in the cells.

There are forty-five different kinesin motor proteins in human body in all. The researchers tracked the movements of each one and found that motor pauses at the end of the microtubules. Later it produces pushing forces to slide the microtubules apart and allow the motor to grow the microtubules. Their findings are reported in Nature Communications recently. They bound microtubules to a microscope slide and added free tubulin subunits together with modified kinesin-5 motor proteins. The results showed that the motor proteins added improve the rate and persistence of microtubule growth.

In conclusion, if we can terminate cancer cell division, new approaches in treatment will come into being. Therefore, understanding more about how kinesin-5 influences microtubule dynamics and its importance in properly segregating genetic material in cell division is of great concern. By the way, Flarebio offers high-quality recombinant proteins like recombinant App at competitive prices.

Scientists find new therapeutic target of Obesity and type 2 diabetes

Obesity and type 2 diabetes are two interrelated kinds of metabolic diseases which do serious harm to the health of contemporary population, and it can lead to coronary heart disease, stroke, fatty liver, neurodegenerative and other complications. If we can try to balance the energy consumption-intake trend more toward the consumption of this end of the tilt, then it will be able to significantly alleviate the symptoms of the disease. White adipose tissue is the main place to store fat in the human body. It can produce "browning" under specific stimulation, which is similar to the metabolic characteristics of brown adipose tissue - high energy consumption and heat production. Therefore, if the white adipose tissue can change the metabolic characteristics, it tends to "brown", will be expected to play a therapeutic effect.

More recently, Prof. Anutosh Chakraborty from the Scripps Research Institute (University of Florida) found a target protein, hexose inositol phosphokinase 1 (IP6K1), which is expected to be used to achieve this effect. Using recombinant rat proteins, they found that IP6K1 itself can affect the metabolic pathway of fat cells regulated by AMPK, which slows down the decomposition and consumption of fat in the body, thus accelerating the accumulation of fat. The results were published in the recent issue of The Journal of Clinical Investigation.

"We found IP6K1 to be a suitable therapeutic target for obesity and type 2 diabetes," said Professor Chakraborty. "We also found that TNP, an inhibitor of IP6K1, alleviates dietary-induced obesity and insulin resistance."

IP6K1 may have a significant effect on the metabolic pattern of white adipose tissue. Its substrate phytate (IP6) promotes AMPK phosphorylation, thereby upregulating PGC1α transcription coactivator and uncoupling protein 1 (UCP1) -mediated thermogenesis in promoting white adipose tissue browning. IP6K1 converts IP6 to inositol hexaphosphate (5-IP7), which no longer activates AMPK, and it inhibits Akt kinases that promote browning at the same time.

Mouse experiments show that cold stimulation can reduce the white adipose tissue IP6K1 levels, thereby increasing the decomposition of fat at this time of heat. When IP6K1 was knocked out in white adipose tissue, the activity of AMPK was increased, and the heat of lipolysis was enhanced significantly. The white adipose tissue showed browning characteristics, including the elevation of browning marker proteins such as UCP1 and PGC1α. When this IP6K1 knockout mouse received a high-fat diet, the propensity to develop obesity and insulin resistance was significantly reduced. The researchers further found that IP6K1 inhibitor TNP in mice can play a similar effect.

"In addition, TNP also promotes weight loss in mice and improves metabolic markers in obese mice," said Professor Chakraborty. Flarebio offers recombinant proteins such as recombinant App at competitive prices.

The new strategy of screening venom peptides aiming at ion channel

The ion channel is an important drug target of pain, autoimmune diseases, tumor and other diseases. The toxin polypeptide of animals is formed in the evolution of hundreds of millions of years, and it is rich in active ion channels. There is an urgent need to find a way to quickly discover toxin peptides aiming at ion channels.

Professor Richard Lerner from the Institute of Immunochemistry of the Shanghai University of Science and Technology (SIAIS) has innovatively proposed an autocrine-based screening method to screen high-throughput peptides for ion channels. The researchers first constructed a set of signaling systems based on autoadhesive detection of ion channels binding to the toxin polypeptide and using recombinant mouse proteins. In this system, the toxin polypeptide can be anchored to the cell membrane by the platelet-derived growth factor receptor transmembrane domain PDGFR-TM and is fused to the TEV protease at the intracellular end of the transmembrane domain. The ion channels are linked to the artificial transcription factor GAL4-VP16 by the TEV protease substrate sequence. TEV protease cleaves its substrate to release GAL4-VP16 and activates the expression of fluorescent protein reporter gene when it binds to the toxin polypeptide. Fluorescent protein-expressing cells can be sorted by flow cytometry.

Using this method, the researchers screened a library of 589 virulent polypeptides for ion channel Kv1.3. They found that 25 of the 27 enriched toxin polypeptides that were the most enriched in the screening were known as Kv1.3 blocker, and their experiments confirmed that the Clltx1 polypeptide from scorpion venom was a novel and highly effective Kv1.3 antagonist. The system further reconstructed the ShK protein from the sea anemone toxin and constructed nearly one million ShK analogues with long-acting properties for screening. The screened ShK analogues showed high Kv1.3 antagonistic potency and no off-target effects on a series of ion channel molecules which are highly similar to Kv1.3. Flarebio offers superior recombinant proteins such as recombinant App at good prices.

New method of treating heart failure is coming

When the heart can't provide enough blood to maintain the body needs and show systolic and diastolic dysfunction, it will show heart failure. Heart failure is a common age-related disease in an aging society, and it is often with poor prognosis.

Ouchi et al from Kumamoto University found through recombinant rat proteins that age and hypertension and other factors will bring a burden on myocardial cells, and myocardial cells secreted by a protein - promote angiogenesis factor protein-like protein 2 will increase. This protein will weaken the regulation of calcium concentration in cardiac cells and other functions, causing decrease of myocardial contractility and triggering heart failure.

The researchers used gene knockout technology to breed mice that couldn’t produce the protein and found that the mice were not as susceptible to heart failure as normal mice. The study also found that moderate exercise can reduce the level of pro-angiogenic factor-like protein 2, helping to prevent heart failure.

The paper was published in the online edition of the journal Nature. The researchers pointed out that in the future, gene therapy can inhibit levels of myocardial angiogenesis factor protein-like protein-2, thus treating heart failure. Flarebio Biotech LLC is a National High-Tech Enterprise with research, production and sales as one. It provides you with good-quality recombinant proteins including recombinant App at great prices.

There are two key genes in epidermis that help a plant keep alive

It is known to all that the body of a plant consists of only three tissue systems - the outermost epidermal tissue, the inner tissue, and the vascular tissue. The epidermis is essential in protecting the body of a plant from external stresses, preventing organ fusions, and determining final organ shapes.

Scientists took Arabidopsis as a model plant and conducted a research using recombinant proteins. Then two kinds of genes, ATML1 and PDF2, have been identified to serve as a key factor involved in the formation of the epidermis. However, there were more remained to be researched about the functional importance of these two genes.

Now, Taku Takahashi and his colleagues at Okayama University in collaboration with a group at the University of Tokyo have provided compeling evidence that the two genes are essential for the growth of embryos in Arabidopsis.

They generated the double loss-of-function mutant of ATML1 and PDF2 and found that the complete loss of these two genes resulted in the embryonic arrest before seed germination.

They confirmed that the inhibition of the expression of ATML1 and PDF2 caused a severe defect in epidermis formation and organ fusions in leaves, stems and flowers.

All the findings provide important information to the understanding of how the identity of epidermal cells is established in the plant embryo. They are also benefit to further studies on how a plant body is formed. Flarebio offers superior recombinant proteins such as recombinant App at competitive prices.

To synthesize new-type proteins using artificial genes

Synthorx, an emerging biotechnology company located in La Jolla of California, is designing a micro-organism which has six gene codes. The approach is to add artificial X and Y base to the original gene system composed of A, T, G, and C. These micro-organisms don't have same kinds in nature, and Synthorx uses them to design new proteins. According to research using recombinant mouse proteins, these proteins are expected to become the cornerstone of future painkillers, antibiotics and targeted cancer drugs.

Romesberg is one of the company founders. Two years ago, nobody made anything useful with new synthetic X and Y bases, but Romesberg made a goal of making use of conventional chemical methods to develop new drugs. This is obviously an extremely complex process.

The birth of X and Y is of course a milestone in the scientific community, but the real challenge of Synthorx is to use these codes to produce new proteins. Theoretically, by simply adding X and Y, number of amino acids for building proteins can be improved up to 172 kinds, but it is only 20 in the natural state. By adding the XY codes to DNA, the cells can use as many as 172 kinds of proteins to build amino acids, which is far more than the original 20 kinds.

By using artificial amino acids, that scientists can make the combination of existing proteins and their target substance stronger so that the effect of drugs can be more potent. Another idea is to enhance the specific combination of proteins and their target substance through artificial amino acids in order to avoid the side effects of protein binding to non-binding target materials.

Currently, a project of Synthorx is dedicated to turn the venom of a kind of spider into a non-opioid and non-addictive painkiller. The CEO of Synthorx Court Turner said, "Although E. coli also can produce insulin, the only way so far for us to obtain extra insulin is to take injections every day."

Adding artificial amino acids to the insulin molecule can make it more durable. Thus, diabetes patients only need insulin injections every few days. There is no doubt that if this technology can be achieved, it will be a revolution. But it is still too early to dream for the wide use of artificial genes. Although artificial genes can produce amino acids, currently we don't have the ability to make proteins with synthetic amino acids. Flarebio offers recombinant proteins of good quality such as recombinant App.

What is the disease that kills millions of American starfish?

Recently a large number of American starfish are found dead caused by strange diseases. There is no exaggerated that it may be called catastrophic. The researchers used recombinant proteins to conduct the research.

"It's staggering, really, the millions of stars that have died. It is not apocalyptic or extreme to say that," says Drew Harvell, a biologist at Cornell University, describing what is widely regarded as one of the worst marine disease events ever recorded.

The starfish is also called sea stars. Millions of the starfish died in recent years. They had their legs curl up and pull away from their bodies, breaking the animals to pieces before they turn to mush, often in a matter of days. Scientists are struggling to find out the reason. Once densely packed onto the rocks and on the ocean floor, the key predators are simply missing from some locations, their numbers cut by 95 percent or more.

As early as in 2013, this phenomenon called Sea Star Wasting Syndrome was noticed by rangers in Olympic National Park in Washington state. It has now been documented from California to Alaska, and led to die-off that is bigger and more widely spread than any seen before.

There was a group of researchers published their findings indicating strong evidence that a virus was causing the disease last year. Now researchers are studying why the so much more widespread and deadly. They are considering how warmer water brought by climate change is affecting the virus, starfish and the ecosystem. "We've had anomalously warm oceans for the last two years. Really, what we would call hot water. It is really the dominant thing to consider," Harvell said.

The problem is urgent to be solved even through it's hard to collect data on a big scale. The sea star is kind of the mascot of the intertidal. We should protect these sea stars, the ocean, the ecosystem, thus protecting ourselves. Flarebio provides recombinant proteins of high quality such as recombinant app.

Scientists discover that a single gene mutation can change entire biological communities

New research through recombinant rat proteins has found that one gene mutation in a single species can trigger great changes in whole biological communities.

Scientists from Trinity College Dublin use bacteria to replicate ecological systems in the lab and found that mutations of a single gene that change how one bacterial species interacts with others had huge structural impacts across their multi-species microbial communities. These mutants produce biofilms according to their ability and many of which cause great health problems in body. It had chain effect on other species and completely changes the structure of the communities.

"We know that predators are hugely important in influencing how ecosystems are structured, as they control the numbers and diversity of other species in the food web. It is incredible that such a small genetic change can cause these mutants to completely alter communities as much as the extinction of something as important as a predator," said Assistant Professor in Zoology at Trinity, Dr Ian Donohue.

The study shows wide scope for fine-scale genetic differences within populations to change entire ecosystems including microbial ones to lakes, forests and marine system.

"It's amazing to know that just one change in a single gene has the potential to have such a huge effect that it can change whole ecosystems," said Deirdre McClean, lead author of the study and PhD Researcher in Zoology at Trinity.

The results will be helpful to disease researchers, drug developers, ecologists and even geneticists. Besides, better understanding of the effect will be critical to develop treatments aimed at manipulating our gut microbiota specifically. Flarebio provides recombinant proteins of good quality like recombinant APP at good prices.

New potential tool of tagging innocuous protein

As we know that proteins and peptides of various sizes and shapes have been used since the early 80s to tag proteins with many different purposes, ranging from affinity purification to fluorescence-based microscopic detection in whole organisms. However, tagging strategies used nowadays run the risk that the native function of the protein may be abolished or compromised by interactions with the tag.

A study using recombinant proteins like recombinant horse proteins published yesterday at Nature Methods proposes the use of two plant protein epitopes, named inntags, as the most innocuous and stable tagging tools in the study of physical and functional interactions of proteins.

The study is leaded by the Molecular Biology Institute of Barcelona and the Joint Programme for Computational Biology of the Institute for Research in Biomedicine (IRB Barcelona) and the Barcelona Supercomputing Center, and University of Barcelona. It has analyzed the available list of polypeptides with known 3D structure to identify among them the most suitable for tagging purposes. Researches have selected the smallest protein domains that still display strong structural determinants to act as antigens, do not generate solubility issues, do not compromise cell fitness and cause no detectable functional and localization effects when fused to other target proteins.

A large series of bioinformatics tools were first used to scan through the entire planet proteome to select those proteins which could have good tagging properties. After manual curation of the in silico results 12 tag candidates were tested in vivo, finding excellent or outstanding properties for all of them. Inntags maintain their integrity, stability, solubility in cell extracts, diffusional mobility and do not cause important functional perturbations that commonly used tags -such as MYC, FLAG or HA- do cause. Moreover, the tests have shown the applicability of Allergen Phl p2 and Heiven Isoform 2 in immunofluorescence and immunoprecipitation analysis of a series of proteins in mouse fibroblasts and hippocampal neurons.

Compared with commonly used tags, inntags are clearly more innocuous. They may be the tools of choice to perform proteome-wide interactome studies, in situ analysis of proteins at the single-molecule level or when the target protein does not offer an obvious functional assay. The tools are believed to open new possibilities for researchers in cellular biology. Flarebio provides superior recombinant proteins such as recombinant APP at competitive prices.

Scientists uncover the mystery of animals making orientations

Researcher Xie Chan from Key Laboratory of Membrane Biology of College of Life Sciences at Peking University and his research team found a protein complex through experiments on Drosophila genomes. This protein complex can make orientations in magnetic field and this protein gene is found in a number of animal species. The researchers named it magnetic induction protein (MagR). Related papers were published online in the journal British Nature Materials, which also publishes many other studies about recombinant proteins like recombinant mouse proteins.

In nature, many species of animals have the ability to perceive the Earth's magnetic field. They can sense direction, strength or inclination of magnetic field, and they take the navigation of such information as a clue. Although multiple biochemical models which have already existed before can explained the ability of such animals, scientists are still not clear about the biological mechanism behind it.

By using assumed biological criteria to screen Drosophila genomes, Xie Can and his research team discovered a protein like polymer - magnetic induction protein. This protein will combine with the component of photosensitive Cryptochrome protein (referred to Cry) and spontaneously align the external magnetic field. Through biochemical and biophysical method, the researchers found that Drosophila missing photosensitive Cryptochrome protein don't have the capability of magnetic induction. This indicates that the photosensitive Cryptochrome protein is a necessary condition to make Drosophila produce magnetic sensing capability, but theoretically photosensitive Cryptochrome protein can't form a "compass" role. Therefore, the researchers believe that only the combination of magnetic induction protein and photosensitive Cryptochrome protein makes the animals get awareness of magnetic field.

The researchers found that the magnetic induction protein and photosensitive Cryptochrome protein complex (MagR / Cry) stably exists in pigeons, butterflies, rats, whales and human body. The researchers said that the mechanism of this protein complex sensing magnetic field is unclear. However, discovery of such a protein complex like a compass makes magnetic induction protein have broad application prospects in the aspect of magnetic field regulating biological processes in the future. Flarebio provides you with high-quality recombinant proteins such as recombinant APP at competitive prices.

Predicting metabolic pathway of protein interactions is still a challenging task

Cellular activity is subject to physical property and function of several proteins which are involved in a variety of biological pathways. By practicality of genome sequencing and high-throughput experimental data, researchers can make use of a variety of computer technologies and recombinant proteins such as recombinant rat proteins to identify the interaction among whole-genome proteins. The comparative assessment technologies of predicting protein-protein interactions have frequent reports in the literature, but they still have no ability to explain a specific biological pathway.

Methods: In order to learn the ability of predicting the interaction among proteins in specific biological pathways, our report is based on analysis of biological pathways of fourteen E. coli cataloged in KEGG database. The database uses the prediction method of protein function link. These methods are simple phylogenetic appearance surgery (phylogenetic profile), adjacent to the gene, ortholog coexist in the same gene cluster, a mirrortree variants and expression similarity.

Conclusion: Our results show that the predicting metabolic pathway of protein interactions is still a challenging task, and some of the methods may reflect the flexible / independent evolutionary history of proteins. These methods have forecasted that function-related proteins involving amino acids, nucleotides, polysaccharides, vitamins and coenzymes family pathway is superior than the random mechanism related to carbohydrates, lipids and energy metabolism. We also conducted similar observation on the interaction among proteins which is associated with environmental information processing.

On the contrary, genetic information processing and special processes which happen in the subset of organisms and are related to sporty proteins link are predicted with relatively-high accuracy. Given the racial pattern as a good enough method to reconstruct the central dogma of protein-protein interactions between the pathways, metabolic pathways are most easily to be predicted using orthologous group neighboring. If not based on a specific pathway, then the similarity method of gene expression is the best choice. Flarebio provides you with good-quality recombinant proteins including recombinant App at good prices.

ZMYND8 protein is able to inhibit the expression of tumor metastasis-related genes

Although this protein reads like a license plate number in European countries very much, ZMYND8 protein has been shown to have the effect of inhibiting metastasis of prostate cancer-related genes. The findings mainly came from the research on cell study and recombinant mouse proteins, and they were published online on July 28th in the journal Molecular Cell.

"These findings are quite important because metastasis is a complex process, and studying tumor metastasis is a big challenge for doctors." Dr. Min Gyu Lee is an associate professor of molecular and cellular oncology. He said, "Tumor metastasis is very important. We need to know the key of how tumor cells obtaining the ability of metastasis and invasion. Understanding how this process happens is crucial for doctors to prevent tumor metastasis. We believe that this study could help medical researchers better know and understand the process."

Dr. Lee's research focuses on the modification of proteins using recombinant proteins, and this step is crucial for gene regulation; wherein the acetylation and methylation of tumor development is the most common. Dr. Lee's research group believed that ZMYND8 is the "reader" of histone. Identifying histone modifications is likely to affect gene expression.

"The effect of histone acetylation and methylation on gene expression may receive the impact of specific binding proteins," said Dr. Lee. They found that ZMYND8 is the "reader" of histone marker H3K4mel and H3K14ac, and both of them are related to tumor metastasis-related genes.

The research team also noted that ZMYND8 also has synergy with another type of tumor marker "Eraser" JARID1D. Mutual cooperation between them can inhibit tumor metastasis-related genes. "These findings reveal an unknown mechanism of tumor metastasis suppressor, i.e. ZMYND8 genes can inhibit the expression of tumor metastasis-related genes through reading histone markers H3K4mel and H3K14ad its synergy with JARID1D."

Flarebio Biotech LLC is a National High-Tech Enterprise with research, production and sales as one. We offer recombinant proteins including recombinant APP at competitive prices.

A novel therapy: to decrease antioxidants to tumor cells

A new study shows that reducing levels of antioxidants in pancreatic cancer cells would help to kill cancer cells, providing a new strategy for the treatment of this infamous fatal disease. The Leng Quangang research team was led by Professor David Tuveson who is very interested in producing recombinant proteins such as recombinant horse proteins.

Each cell would produce oxides and antioxidants: when the cell is healthy, both of them would stay in balance. What the treatment of Leng Quangang research team hopes to develop is to make cell die in malignant stage or before by increasing intracellular levels of oxides.

When the cell finds the oxide is superabundant, it will follow an established principle which is called apoptosis to commit suicide. One of the methods of increasing oxide levels in cancer is to reduce the levels of antioxidants therein. How to do this to best without harming healthy cells? The researchers focused mostly on a protein called NRF2, which can destroy the balance between the oxide and antioxidants within the cell.

When NRF2 is activated, a compound called glutathione would be synthesized in the cells. It is an important antioxidant. So, reducing the activity of NRS or knocking it becomes a matter of course. However, due to two reasons, it is difficult to be done. One of the reasons is that it is a transcription factor, a protein that regulates other genes. The researchers used to use recombinant dog proteins to conduct part of the experiment. Transcription factors are notoriously difficult to be regulated by target drugs. "But in any case you might not want to knock it, because NRF also regulate hundreds of different genes in addition to promoting the synthesis of glutathione." Chio said. No one can knock out a gene which affects many cellular processes.

Tuveson, Chio and other colleagues proposed alternative strategies after conducting experiments on pancreatic cancer cells of animal model in the laboratory and tried out several therapeutic measures. Making use of a class of pancreas organs, they observed the situation after NRF2 was knocked out. The experiment was divided into normal group, pre-cancerous cell group and cancer cell group. Pre-cancerous cell group showed kras mutations. This gene is mutated in almost all human pancreatic cancer cells. In addition to gene mutation, a gene which made p53 gene inactivating in cancer cell group also showed mutation. p53 gene is a powerful tumor suppressor gene. In most human malignancies, these two genes would have mutated.

These experiments give an important clue: when NRF2 is lost, the translation mechanism within the cell becomes very sensitive to the balance between oxide and antioxidants. Translation is the process of cells creating proteins according to genes. What is essential is that normal cells are unaffected. This means that as long as reducing the levels of antioxidants, the protein synthesis in pre-cancerous cells and cancer cells are affected, while normal cells are not affected. This could become a powerful therapeutic tool. Flarebio provides high-quality recombinant proteins such as recombinant APP.

Fluorescence lifetime imaging technology makes the treatment of breast cancer more effective

According to a recently-published study, scientists from UK Cancer Research Centre have taken imaging technology as a new way to identify which treatments of breast cancer that the patients are likely to benefit from. Research team from Imperial College London and scientists at Oxford United Radiation Oncology Institute of Science made use of fluorescence lifetime imaging to determine whether they have been connected together. The process also involved many kinds of recombinant proteins such as recombinant dog proteins.

Fluorescence lifetime imaging is a new technology that can accurately measure the distance between the two protein molecules. In this study, the researchers measured the distance between the two proteins HER2 and HER3 from breast cancer cells of a patient. The researchers believed that the imaging results showed that the patients with these proteins connected together can benefit from HER2 targeting therapy, regardless of whether their tumors have higher levels of HER2.

HER2 is a protein can cause the growth of cancer cells. Positive HER2 which shows high levels in breast cancer cells is taken as drug targets. Blocking its effect can prevent growth of cancer cells. The present drugs which are used include Herceptin and lapatinib. Whether patients benefit from these drugs are mainly determined by detecting whether cancer cells have high levels of HER2 protein. However, in those who have better response to HER2-targeted drugs, this imaging technology implemented in tumor cells may obtain other information about proteins. This technology can also be able to determine which patients may be unsuitable for these treatments.

Professor Tony Ng at Imperial College London said, "This imaging technology can help us determine which patients can benefit from these drugs while it had been ignored before. We should predict which drugs will not work in a patient when applying this test in order to avoid some unnecessary treatments - this can help us better use the drug. The next step is to conduct a clinical trial to see if this test can help patients. We hope that one day it not only can improve the treatment of breast cancer, but also be effective on other cancers including colon cancer and lung cancer."

Nell Barrie from UK Cancer Research said, "There are more than 50,000 new cases of breast cancer. But thanks to the new progress in the study, more people have survived from this disease than before. This research may ultimately provide the doctor with another way for personalized treatment so that patients can receive medications that are more likely to help them." Flarebio offers many other recombinant proteins such as recombinant App of good quality.

Vitamin D is associated with mucosal inflammation of patients with Ulcerative colitis

According to the results of a prospective study, the concentration of serum 25-hydroxy vitamin D and mucosal inflammation in patients with ulcerative colitis are negatively correlated with disease activity. The treatment of UC includes the technologies of recombinant proteins. Related content has been published online in the journal The American Journal of Clinical Nutrition.

"The incidence of Vitamin D deficiency is very high in patients with inflammatory bowel disease." Said Dr. Joel Pekow at Digestion Department of University of Chicago. Pekow and colleagues evaluated concentration of serum 25-hydroxyvitamin D of 230 UC patients [25 (OH) D] (mean age 45.8 years; the average duration, 166 years; 53% male; 90% Caucasian) and compared their inner Mayo endoscopic scores, overall Mayo score and histological activity. They also compared expression concentration of colonic mucosa epithelium connected proteins and inflammatory cytokines in patients with low serum 25 (OH) D concentrations and high serum 25 (OH) D concentrations relatively low serum 25 (OH) D concentrations and high serum 25 (OH) D concentrations to determine whether enough levels of vitamin D is related to the protection of epithelial cell junction proteins and the reduce of gastric mucosa inflammatory cytokines. The research also used various recombinant dog proteins.

"The vast majority of UC patients have deficiency or insufficiency of vitamin D, mucosal inflammation in patients with ulcerative colitis is related to the decrease of serum 25 (OH) D levels," Pekow said. The overall serum 25 (OH) D concentration was 21.8ng / ml, and serum 25 (OH) D concentration Mayo endoscopy score (P = 0.01), overall Mayo score (P = 0.001) and histological activity (P = 0.02) were negatively correlated.

In addition, the condition of serum 25 (OH) D concentration is less than 20ng / ml is related to mucous membranes reduce transcription, vitamin D receptor (VDR) and a closed-cadherin protein expression concentration. In contrast, in patients with serum 25 (OH) D concentrations below 20ng / ml, pro-inflammatory cytokines TNF-α and mucosa transcriptional expression concentration of interleukin-8 increased. "In UC patients, serum 25 (OH) levels were proportional to mucosal expression of VDR and epithelial cell connected proteins and inversely proportional to the pro-inflammatory cytokines. The results support investigation that vitamin D is effective protection of active inflammation of UC." Pekow Said. Flarebio can provide you with high-quality recombinant proteins such as recombinant APP, please stay tuned.

New study may show direction for relevant pharmaceutical researchers of Ebola virus

The Ebola virus which began to spread in West Africa since 2013 is the most serious outbreak of Ebola haemorrhagic fever by far. It has made nearly 30,000 people sick and more than 10,000 deaths, leaving millions of people with the most horrible memories. Although the epidemic has subsided, the high mortality rate of Ebola haemorrhagic fever is very high and still has no effective treatment. Thus, once comeback, it still could result in disastrous consequences. Therefore, researchers from all the nations were nose to the grindstone and are racing against time to develop drugs for the treatments of Ebola hemorrhagic fever. And a new study is expected to indicate a new direction for the relevant pharmaceutical researchers. There used to have some vaccine technologies using recombinant mouse proteins and recombinant rat proteins and they had also won success in animal experiments.

There had been computer simulation, in-vitro and animal studies suggested that some drugs which had been approved for the treatment of other diseases may have certain inhibiting effect on Ebola virus, but the functional mechanism of these drugs was unclear. Researchers from the United Kingdom indicated through experiments that the common painkiller ibuprofen and chemotherapeutic drug Toremifene can be combined with glycoprotein in Ebola virus and reduce its stability. The researchers used X-ray to measure the structures of glycoproteins of Ebola virus before and after they interacted with the two drugs and to determine the parts where drugs interact with glycoproteins. When the Ebola virus tries to infect host cells, it first needs to use its own glycoprotein to adsorb onto the host cells, so many researchers take glycoprotein of Ebola virus as an important target for drug development. Then recombinant animal proteins such as recombinant horse proteins can play their roles in the research.

This study is exciting, because drug-developers can specifically develop the drug treatment of Ebola haemorrhagic fever according the information of these structures. In particular for the drugs which have been approved for marketing, if they are possible to inhibit Ebola virus, the time required for clinical trials may be significantly shorter than new drugs, because the safety of these drugs have been shown without the need of validation through clinical trials. But the experts also warned it still needs a lot of time for us to develop effective drugs, especially the two drugs ibuprofen and toremifene mentioned by the study may not really be able to have effect on the treatment of Ebola hemorrhagic fever in clinical trials. Flarebio is a biocompany which produces recombinant proteins such as recombinant APP of good quality.

Expression levels of CD38 and CIP can significantly affect daratumumab sensitivity

Related studies have shown that anti CD38 monoclonal antibody daratumumab can treat severe relapsed / refractory multiple myeloma (MM). This antibody is well tolerated and has high single-agent activity. However, not all patients will respond to the drug, and even some patients eventually have more disease progression. A recent study published in the journal Blood was designed to investigate the effect of CD38 and the level of expression of complement regulatory protein (CIPs) before treatment on the response and whether this protein expression can lead to drug resistance. Recombinant dog proteins are used in the research.

The study included 102 MM patients who had received daratumumab monotherapy (16 mg / kg). The researchers found that at least a majority of patients with response (PR) before treatment had significantly higher levels of CD38 expression in MM cells, while patients who had no PR showed lower levels of CD38 expression. However, the cellular surface expression of CIPs, CD46, CD55 and CD59 was independent to clinical response.

In addition, after injecting daratumumab for the first time, CD38 expression of bone marrow and circulating MM cells decreased; after withdrawal of daratumumab, CD38 expression levels of MM cells rise again. In contrast, only at the time of disease progression, CD55 and CD59 expression of MM cells will increase. All-trans retinoic acid increased the MM cells CD38 levels of patients with resistance to daratumumab and reduced the expression of CD55 and CD59, which makes daratumumab mediated complement-dependent cytotoxicity significantly enhanced.

Together, these data demonstrate that the expression levels of CD38 and CIP can significantly affect daratumumab sensitivity. This reminds us that the next step should be to explore to MM combination therapy strategies which can change the expression levels of CD38 and CIP. For more information about proteins like recombinant App, you can visit Cusabio’s website.

High-sensitivity cardiac troponin I assay is beneficial to rule out acute myocardial infarction

A recent study published in the journal JAMA Cardiology shows that detection of high-sensitivity cardiac troponin I can help to identify or rule out whether a patient with chest pain emergency has suffered from myocardial infarction. Although the current US guidelines haven't recommended the application of high-sensitivity cardiac troponin I testing, the technology can indeed rule out acute myocardial infarction more quickly. The journal also published some other famous studies on the development of different recombinant proteins, such as recombinant human proteins, recombinant dog proteins, recombinant rat proteins and recombinant horse proteins.

Johannes Tobias Neumann from the University Heart Center in Hamburg of Germany and other researchers analyzed three queues (BACC, ADAPT and APACE) and found an optimal troponin I threshold for the diagnosis of NSTEMI. They developed and verified a more accurate method of diagnosis and exclusion of acute myocardial infarction.

First, the researchers used the data of BACC queue and found the optimal threshold 6ng / L and developed a fast approach of diagnosis of acute myocardial infarction. European Society of Cardiology guidelines suggest emergency physician conduct high-sensitivity cardiac troponin I tests after the patient reaches the hospital and three hours later. The results show that using the critical value of troponin diagnostic applications resulting type 1 NSTEMI negative predictive value is 99.8% (95% CI, 98.6-100), only one false-negative findings; negative predictive value of all NSTEMI patients is 99% (95% CI, 97.5-99.7) and four false-negative cases were found.

When using 1 hour diagnostic method to measure levels of cardiac troponin I, the negative predictive value 1 type NSTEM was 99.8% (95% CI, 98.6-100)1 hour later; 3 hours later it came to 100% (95% CI, 98.5- 100). In all NSTEMI patients, 406 cases (39%) of patients can be discharged, among which four patients were false-negative (negative predictive value 99%; 95% CI, 97.5-99.7). The results were very precise and recombinant APP played an important role.

When using threshold troponin diagnosis of myocardial infarction, the positive predictive value of one hour diagnosis of Type 1 NSTEMI I was 82.8% (95% CI, 73.2-90), and 3 hours later it came to 78.6% (95% CI, 69.8- 85.8). In all NSTEMI patients, the positive predictive value of 1 hour 87.1% (95% CI, 79.6-92.6), 3 hours of 84.6% (95% CI, 78-89.9).

The researchers identified the method in ADAPT and APACE queue. In ADAPT queue, 1748 patients received two hours of law verification and 249 cases of NSTEMI were found. Admission negative predictive value was 99.6% (95% CI, 99.1-99.9), and 2 hours later it was 99.7% (95% CI, 99.2-99.4). In the diagnostic process, the positive predictive value was 81.5% (95% CI, 75.3-86.3). APACE queue used a similar method of one hour and three hours. In the queue, negative predictive value on admission was 98.6% (95% CI, 98.6-99.2), and 1 hour later it was 99.2% (95% CI, 98.4-99.2 ) and 99.1% (95% CI, 97.1-99.8) after 3 hours; 1 hour later the positive predictive value was 80.4% (95% CI, 75.1-84.9) and 3 hours later it was 68.8% (95% CI, 59.2- 77.3). Transmembrane protein plays an important role in basic physiological processes, including molecule transport, signal transduction, energy utilization and so on. Cusabio offers recombinant proteins of good quality.